Seeking Alpha

An FDA Advisory Committee has voted unanimously in support of the use of Novartis' (NVS)...

An FDA Advisory Committee has voted unanimously in support of the use of Novartis' (NVS) Signifor, a treatment for patients with Cushing's disease who require medical therapeutic intervention. The drug is the first of its kind for this potentially debilitating endocrine disorder caused by a pituitary tumor that triggers excess cortisol. Phase III clinical trials showed patients who used Signifor experienced a rapid and sustained decrease in mean cortisol levels.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|